Inactive Instrument

Forward Pharma A/S

Equities

FWPAY

US34986J3032

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Reopening Prospects Lend Some Support to European Equities But Uncertain Outlook Weighs MT
European Equities Broadly Flat Amid End of Chinese COVID-19 Quarantine Restrictions MT
Forward Pharma A/S(OTCPK:FWPA.Y) dropped from NASDAQ Composite Index CI
European Equities Rise Modestly in Friday Trading, End Week Up 1% MT
European Equities Buoyed by Financial, Pharma Stocks in Tuesday Trading MT
Top Midday Decliners MT
European Equities Lose Early Momentum, Remain Relatively Flat in Monday Trading MT
Forward Pharma Says it Expects to Be Delisted From Nasdaq; Shares Plunge MT
Biotechnology Gains Lead European Equities Higher in Wednesday Trading MT
European Equities Rise Modestly Friday, But End Week Lower MT
European Equities Nudge Higher on Slightly Lower Euro Area Inflation MT
Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday Trading MT
European Markets Move Higher Helped by Upbeat US Inflation Data MT
European ADRs Continue to Trend Higher in Monday Trading MT
European ADRs Surge Higher as Global Markets React to US Inflation Data MT
Forward Pharma A/S Reports Earnings Results for the Half Year Ended June 30, 2022 CI
European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains MT
European ADRs Move Lower in Monday Trading MT
European ADRs Move Higher in Thursday Trading MT
European ADRs Climb Sharply Higher in Monday Trading MT
European ADRs Move Higher in Thursday Trading MT
European ADRs Move Higher in Friday Trading MT
European ADRs Move Lower in Wednesday Trading MT
European ADRs Move Lower in Tuesday Trading MT
European ADRs Move Lower in Thursday Trading MT
Chart Forward Pharma A/S
More charts
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
More about the company